我們已在上線！進一步了解

CAMP4 Therapeutics

CAMP

市值 US$1.99億

3.17 USD

-0.28

8.12%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

3.17

0.00

0%

1天

-8.12%

5天

-14.56%

1個月

-17.88%

3個月

-18.72%

6個月

-29.56%

今年迄今

-47.17%

1年

1.93%

5年

-70.43%

10年

-70.43%

關於： Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.

員工： 48

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 8.3%

中性 83.3%

負面 8.3%

CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference

WATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the company will participate in a panel during Chardan's 10th Annual Healthcare Conference on October 20, 2026. Details below:

CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics NASDAQ: CAMP said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028.

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4's executive leadership team and participation from patient advocates and a leading KOL. To register, click here.

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

CAMP4 to Participate in Upcoming Investor Conferences

Zacks Investment Research

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at least 30 children ages 2 to 18 and use a double-blind, placebo-controlled design, with placebo recipients able to transition to the treatment if early results are positive.

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

查看新聞排名

價格圖表採用Lightweight Charts™實作